New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
Solanezumab does not slow cognitive decline in preclinical Alzheimer disease

Solanezumab does not slow cognitive decline in preclinical Alzheimer disease

by Elana GotkineFor patients with preclinical Alzheimer disease, solanezumab does not slow cognitive decline, according to a study published online July 17 in theNew England Journal of Medicine&
Neurology April 02,2024
Solanezumab does not slow cognitive decline in preclinical Alzheimer disease

Solanezumab does not slow cognitive decline in preclinical Alzheimer disease

by Elana GotkineFor patients with preclinical Alzheimer disease, solanezumab does not slow cognitive decline, according to a study published online July 17 in theNew England Journal of Medicine&
Neurology April 02,2024
Tau-regulating protein identified as a promising target for developing Alzheimer's disease treatment

Tau-regulating protein identified as a promising target for developing Alzheimer's disease treatment

by Perelman School of Medicine at the University of PennsylvaniaIndividuals with Alzheimer’s disease (AD) have increased neurofibrillary tangles (NFTs) of tau proteins but reduced TRIM11, as show
Neurology April 02,2024
Tau-regulating protein identified as a promising target for developing Alzheimer's disease treatment

Tau-regulating protein identified as a promising target for developing Alzheimer's disease treatment

by Perelman School of Medicine at the University of PennsylvaniaIndividuals with Alzheimer’s disease (AD) have increased neurofibrillary tangles (NFTs) of tau proteins but reduced TRIM11, as show
Neurology April 02,2024
New insight into role of amyloid beta in Alzheimer's disease

New insight into role of amyloid beta in Alzheimer's disease

by Tamara Bhandari,Washington University School of Medicine in St. LouisA new technique for measuring levels in the brain of amyloid beta, a key protein associated with Alzheimer’s disease, woul
Neurology April 02,2024
New insight into role of amyloid beta in Alzheimer's disease

New insight into role of amyloid beta in Alzheimer's disease

by Tamara Bhandari,Washington University School of Medicine in St. LouisA new technique for measuring levels in the brain of amyloid beta, a key protein associated with Alzheimer’s disease, woul
Neurology April 02,2024
Seeing Alzheimer's disease

Seeing Alzheimer's disease

by University of MinnesotaCredit: University of MinnesotaWhat if we could diagnose early-stage Alzheimer's disease (AD) by looking into a person's eyes?A retinal scan technique, developed
Neurology April 02,2024
Seeing Alzheimer's disease

Seeing Alzheimer's disease

by University of MinnesotaCredit: University of MinnesotaWhat if we could diagnose early-stage Alzheimer's disease (AD) by looking into a person's eyes?A retinal scan technique, developed
Neurology April 02,2024
Patients with Alzheimer's disease, dementia face twice the risk of dying after ICU discharge

Patients with Alzheimer's disease, dementia face twice the risk of dying after ICU discharge

by American Association of Critical-Care Nurses (AACN)Outcomes after a stay in the intensive care unit for patients in cohorts with versus without Alzheimer disease and related dementia (ADRD). Credit
Neurology April 02,2024
Patients with Alzheimer's disease, dementia face twice the risk of dying after ICU discharge

Patients with Alzheimer's disease, dementia face twice the risk of dying after ICU discharge

by American Association of Critical-Care Nurses (AACN)Outcomes after a stay in the intensive care unit for patients in cohorts with versus without Alzheimer disease and related dementia (ADRD). Credit
Neurology April 02,2024
Tau does not stabilize microtubules, challenges approach to treating Alzheimer's

Tau does not stabilize microtubules, challenges approach to treating Alzheimer's

by Drexel UniversityThis image represents the role of tau and MAP6 in regulating the stable (green) and dynamic (red) parts of a neuron's microtubules. Depleting tau from cultured rat neurons
Neurology April 02,2024
Tau does not stabilize microtubules, challenges approach to treating Alzheimer's

Tau does not stabilize microtubules, challenges approach to treating Alzheimer's

by Drexel UniversityThis image represents the role of tau and MAP6 in regulating the stable (green) and dynamic (red) parts of a neuron's microtubules. Depleting tau from cultured rat neurons
Neurology April 02,2024
How SORLA protects against Alzheimer's disease

How SORLA protects against Alzheimer's disease

by Sanford-Burnham Prebys Medical Discovery InstituteHuaxi Xu, Ph.D., Professor, Neuroscience and Aging Research Center. Credit: Sanford Burnham Prebys Medical Discovery Institute (SBP)Researcher
Neurology April 02,2024
How SORLA protects against Alzheimer's disease

How SORLA protects against Alzheimer's disease

by Sanford-Burnham Prebys Medical Discovery InstituteHuaxi Xu, Ph.D., Professor, Neuroscience and Aging Research Center. Credit: Sanford Burnham Prebys Medical Discovery Institute (SBP)Researcher
Neurology April 02,2024
Molecular alterations in neuronal trophic regulation in Alzheimer's pathology

Molecular alterations in neuronal trophic regulation in Alzheimer's pathology

by Jason Clement,McGill UniversityCredit: Unsplash/CC0 Public DomainFor decades researchers have known that Alzheimer's disease (AD) causes the atrophy of a system of neurons and synapses hi
Neurology April 02,2024
Molecular alterations in neuronal trophic regulation in Alzheimer's pathology

Molecular alterations in neuronal trophic regulation in Alzheimer's pathology

by Jason Clement,McGill UniversityCredit: Unsplash/CC0 Public DomainFor decades researchers have known that Alzheimer's disease (AD) causes the atrophy of a system of neurons and synapses hi
Neurology April 02,2024
Development of plaques in Alzheimer's disease resolved

Development of plaques in Alzheimer's disease resolved

by Ruhr-Universitaet-BochumDominik Röhr researches proteins that are altered in Alzheimer’s disease. Credit: Michael SchwettmannA team of researchers from Ruhr-Universität Bochum (RUB) and Vrije
Neurology April 02,2024
Development of plaques in Alzheimer's disease resolved

Development of plaques in Alzheimer's disease resolved

by Ruhr-Universitaet-BochumDominik Röhr researches proteins that are altered in Alzheimer’s disease. Credit: Michael SchwettmannA team of researchers from Ruhr-Universität Bochum (RUB) and Vrije
Neurology April 02,2024
Tauvid receives approval for tau pathology imaging

Tauvid receives approval for tau pathology imaging

(HealthDay)—Tauvid (flortaucipir F18), a radioactive diagnostic agent, was approved to image tau pathology in patients with cognitive impairment being evaluated for Alzheimer disease, the U.S. Food an
Neurology April 02,2024
Tauvid receives approval for tau pathology imaging

Tauvid receives approval for tau pathology imaging

(HealthDay)—Tauvid (flortaucipir F18), a radioactive diagnostic agent, was approved to image tau pathology in patients with cognitive impairment being evaluated for Alzheimer disease, the U.S. Food an
Neurology April 02,2024
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com